Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
Abstract: This article discusses the role that melatonin may have in the prevention and treatment of Parkinson’s disease (PD). In parkinsonian patients circulating melatonin levels are consistently disrupted and the potential therapeutic value of melatonin on sleep disorders in PD was examined in a limited number of clinical studies using 2–5mg/ day melatonin at bedtime. The low levels of melatonin MT1 and MT2 receptor density in substantia nigra and amygdala found in PD patients supported the hypothesis that the altered sleep/wake cycle seen in PD could be due to a disrupted melatonergic system. Motor symptomatology is seen in PD patients when about 75%of the dopaminergic cells in the substantia nigra pars compacta region degenerate. Nevertheless, symptoms like rapid eye movement (REM) sleep behavior disorder (RBD), hyposmia or depression may precede the onset of motor symptoms in PD for years and are index of worse prognosis. Indeed, RBD patients may evolve to an α-synucleinopathy within 10 years of RBD onset. Daily bedtime administration of 3–12 mg of melatonin has been demonstrated effective in RDB treatment and may halt neurodegeneration to PD. In studies on animal models of PD melatonin was effective to curtail symptomatology in doses that allometrically projected to humans were in the 40–100 mg/day range, rarely employed clinically. Therefore, double-blind, placebo-controlled clinical studies are urgently needed in this respect.
Autores principales: | Pérez Lloret, Santiago, Cardinali, Daniel Pedro |
---|---|
Formato: | Artículo biblioteca |
Idioma: | eng |
Publicado: |
Frontiers Media
2021
|
Materias: | MELATONINA, ENFERMEDAD DE PARKINSON, ENVEJECIMIENTO, NEURODEGENERACION, ENFERMEDADES NEURODEGENERATIVAS, TRATAMIENTO MEDICO, |
Acceso en línea: | https://repositorio.uca.edu.ar/handle/123456789/11620 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Melatonin : clinical perspectives in neurodegeneration
por: Cardinali, Daniel Pedro
Publicado: (2019) -
The renin–angiotensin system modulates dopaminergic neurotransmission : A new player on the scene
por: Kobiec, Tamara, et al.
Publicado: (2021) -
Pharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration
por: Pérez Lloret, Santiago, et al.
Publicado: (2016) -
Neuroprotective properties of cannabinoids in cellular and animal models : hypotheses and facts
por: Udovin, Lucas Daniel, et al.
Publicado: (2020) -
Therapeutical implications of melatonin in alzheimer’s and parkinson’s diseases
por: Cardinali, Daniel Pedro, et al.
Publicado: (2015)